Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 309

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial

Open access
Sissoko, Mahamadou S, Healy, Sara A, Katile, Abdoulaye, Omaswa, Freda, Zaidi, Irfan, Gabriel, Erin E, Kamate, Bourama, Samake, Yacouba, Guindo, Merepen A, Dolo, Amagana, Niangaly, Amadou, Niaré, Karamoko, Zeguime, Amatigue, Sissoko, Kourane, Diallo, Hama, Thera, Ismaila, Ding, Kelly, Fay, Michael P, O'Connell, Elise M, Nutman, Thomas B, Wong-Madden, Sharon, Murshedkar, Tooba, Ruben, Adam J, Li, Minglin, Abebe, Yonas, Manoj, Anita, Gunasekera, Anusha, Chakravarty, Sumana, Sim, B Kim Lee, Billingsley, Peter F, James, Eric R, Walther, Michael, Richie, Thomas L, Hoffman, Stephen L, Doumbo, Ogobara, Duffy, Patrick E·2017·The Lancet Infectious Diseases

Abstract

Summary Background Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection in malaria-naive individuals. We aimed to assess the safety and protective efficacy of PfSPZ Vaccine against naturally acquired P falciparum in malaria-experienced adults in Mali. Methods After an open-label dose-escalation study in a pilot safety cohort, we did a double-blind, randomised, placebo-controlled trial based in Donéguébougou and surrounding villages in Mali. We recruited 18–35-year-old healthy adults who were randomly assigned (1:1) in a double-blind manner, with stratification by village and block randomisation, to receive either five doses of 2·7 × 105 PfSPZ or normal saline at days 0, 28, 56, 84, and 140 during the dry season (January to July inclusive). Participants and investigators were masked to group assignments, which were unmasked at the final study visit, 6 months after receipt of the last vaccination. Participants received combined artemether and lumefantrine (four tablets, each containing 20 mg artemether and 120 mg lumefantrine, given twice per day over 3 days for a total of six doses) to eliminate P falciparum before the first and last vaccinations. We collected blood smears every 2 weeks and during any illness for 24 weeks after the fifth vaccination. The primary outcome was the safety and tolerability of the vaccine, assessed as local and systemic reactogenicity and adverse events. The sample size was calculated for the exploratory efficacy endpoint of time to first P falciparum infection beginning 28 days after the fifth vaccination. The safety analysis included all participants who received at least one dose of investigational product, whereas the efficacy analyses included only participants who received all five vaccinations. This trial is registered at ClinicalTrials.gov, number . Findings Between Jan 18 and Feb 24, 2014, we enrolled 93 participants into the main study cohort with 46 participants assigned PfSPZ Vaccine and 47 assigned placebo, all of whom were evaluable for safety. We detected no significant differences in local or systemic adverse events or laboratory abnormalities between the PfSPZ Vaccine and placebo groups, and only grade 1 (mild) local or systemic adverse events occurred in both groups. The most common solicited systemic adverse event in the vaccine and placebo groups was headache (three [7%] people in the vaccine group vs four [9%] in the placebo group) followed by fatigue (one [2%] person in the placebo group), fever (one [2%] person in the placebo group), and myalgia (one [2%] person in each group). The exploratory efficacy analysis included 41 participants from the vaccine group and 40 from the placebo group. Of these participants, 37 (93%) from the placebo group and 27 (66%) from the vaccine group developed P falciparum infection. The hazard ratio for vaccine efficacy was 0·517 (95% CI 0·313–0·856) by time-to-infection analysis (log-rank p=0·01), and 0·712 (0·528–0·918) by proportional analysis (p=0·006). Interpretation PfSPZ Vaccine was well tolerated and safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria season.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(17)30104-4

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 309

Metadata

Authors
Sissoko, M. S., Healy, S. A., Katile, A., Omaswa, F., Zaidi, I., Gabriel, E. E., Kamate, B., Samake, Y., Guindo, M. A., Dolo, A., Niangaly, A., Niaré, K., Zeguime, A., Sissoko, K., Diallo, H., Thera, I., Ding, K., Fay, M. P., O'Connell, E. M., Nutman, T. B., Wong-Madden, S., Murshedkar, T., Ruben, A. J., Li, M., Abebe, Y., Manoj, A., Gunasekera, A., Chakravarty, S., Sim, B. K. L., Billingsley, P. F., James, E. R., Walther, M., Richie, T. L., Hoffman, S. L., Doumbo, O., & Duffy, P. E.
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2017-05
Volume
17
Issue
5
Pages
498-509
ISSN
1473-3099 (ISSN-L)
OpenAlex
W2587907012
Cited by
309
References
27
FWCI
32.99
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. https://app.cochat.ai/papers/10.1016/s1473-3099(17)30104-4
The paper
Sissoko, M. S., Healy, S. A., Katile, A., Omaswa, F., Zaidi, I., Gabriel, E. E., Kamate, B., Samake, Y., Guindo, M. A., Dolo, A., Niangaly, A., Niaré, K., Zeguime, A., Sissoko, K., Diallo, H., Thera, I., Ding, K., Fay, M. P., O'Connell, E. M., . . . Duffy, P. E. (2017). Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(17)30104-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.